← Leaderboards
Haojie Huang
University Of Minnesota
$10,928,769
Attributed
$10,928,769
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2009–22$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$10,928,769 · 5
By mechanism
R01$10,928,769 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota
Same institution · by research overlap
- Nobuaki Kikyo$6,960,699
- Kim Carpenter Mansky$4,205,284
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingDesignMalignant Neoplasm Of ProstateMolecularPlayTumorPhosphorylationProstate Cancer CellResistanceGenetic TranscriptionLeadProstate Cancer TherapyClinically SignificantCessation Of LifeProstateMalignant NeoplasmsGenesCell SurvivalProstatic NeoplasmsBaseCastration Resistant Prostate CancerOncogenicCancer PatientCancer Etiology
Grant awards (33)
Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis$506,326
R01 · FY2022 · CA · contact PI
Mechanism and role of aberrant AR activity in castration-resistant prostate cancer$356,438
R01 · FY2022 · CA · contact PI
Role of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancer$377,625
R01 · FY2021 · CA · contact PI
Mechanism and role of aberrant AR activity in castration-resistant prostate cancer$363,713
R01 · FY2021 · CA · contact PI
Role of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancer$377,625
R01 · FY2020 · CA · contact PI
Mechanism and role of aberrant AR activity in castration-resistant prostate cancer$363,713
R01 · FY2020 · CA · contact PI
Role of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancer$366,296
R01 · FY2019 · CA · contact PI
Mechanism and role of aberrant AR activity in castration-resistant prostate cancer$352,801
R01 · FY2019 · CA · contact PI
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression$352,801
R01 · FY2019 · CA · contact PI
Role of FOXO1 Inactivation in Prostate Tumorigenesis$347,017
R01 · FY2019 · CA · contact PI
Role of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancer$377,625
R01 · FY2018 · CA · contact PI
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression$363,713
R01 · FY2018 · CA · contact PI
Mechanism and role of aberrant AR activity in castration-resistant prostate cancer$363,713
R01 · FY2018 · CA · contact PI
Role of FOXO1 Inactivation in Prostate Tumorigenesis$357,750
R01 · FY2018 · CA · contact PI
Role of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancer$377,625
R01 · FY2017 · CA · contact PI
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression$363,713
R01 · FY2017 · CA · contact PI
Role of FOXO1 Inactivation in Prostate Tumorigenesis$357,750
R01 · FY2017 · CA · contact PI
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression$363,713
R01 · FY2016 · CA · contact PI
Role of FOXO1 Inactivation in Prostate Tumorigenesis$357,750
R01 · FY2016 · CA · contact PI
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression$363,713
R01 · FY2015 · CA · contact PI
Role of FOXO1 Inactivation in Prostate Tumorigenesis$357,750
R01 · FY2015 · CA · contact PI
Mechanism of promiscuous AR activation in PTEN-mutated prostate cancer$327,228
R01 · FY2015 · CA · contact PI
Mechanism of promiscuous AR activation in PTEN-mutated prostate cancer$317,411
R01 · FY2014 · CA · contact PI
Mechanism of promiscuous AR activation in PTEN-mutated prostate cancer$307,594
R01 · FY2013 · CA · contact PI
FOXO1 Inhibition in Genotoxic Stress Response and Prostate Cancer Survival$298,367
R01 · FY2013 · CA · contact PI
Mechanism of promiscuous AR activation in PTEN-mutated prostate cancer$319,323
R01 · FY2012 · CA · contact PI
FOXO1 Inhibition in Genotoxic Stress Response and Prostate Cancer Survival$317,411
R01 · FY2012 · CA · contact PI
FOXO1 Inhibition in Genotoxic Stress Response and Prostate Cancer Survival$217,876
R01 · FY2011 · CA · contact PI
FOXO1 Inhibition in Genotoxic Stress Response and Prostate Cancer Survival$92,767
R01 · FY2011 · CA · contact PI
FOXO1 Inhibition in Genotoxic Stress Response and Prostate Cancer Survival$313,325
R01 · FY2010 · CA · contact PI
Mechanism of promiscuous AR activation in PTEN-mutated prostate cancer$228,802
R01 · FY2010 · CA · contact PI
Mechanism of promiscuous AR activation in PTEN-mutated prostate cancer$106,170
R01 · FY2010 · CA · contact PI
FOXO1 Inhibition in Genotoxic Stress Response and Prostate Cancer Survival$313,325
R01 · FY2009 · CA · contact PI